Cinnaxole Pharma

Company Overview

Snapshot

Founded in December 2014 by Zvika Weiss and Tomer Cohen, Cinnaxole Pharma operates with 1–10 employees. The company is currently in the Pre-Funding stage, focusing on research and development for its innovative antiviral solutions.

Business overview

Cinnaxole Pharma is a Health Tech & Life Sciences company developing cinnamon-based antiviral extracts for vaccinations against envelope virus diseases. Its core technology focuses on biologicals to create more efficient and cost-effective in-ovo vaccinations, initially targeting Newcastle disease in domestic poultry. The company operates within the agriculture and food sector, specifically serving the livestock and poultry markets with its veterinary solutions.

Company Intelligence Q&A

What is Cinnaxole Pharma's primary focus?

Cinnaxole Pharma is focused on developing antiviral vaccines for poultry, utilizing a cinnamon-based extract to combat envelope virus diseases.

When was Cinnaxole Pharma founded?

Cinnaxole Pharma was founded in December 2014.

Who are the founders of Cinnaxole Pharma?

The company was co-founded by Zvika Weiss and Tomer Cohen.

What is Cinnaxole Pharma's initial product target?

Cinnaxole Pharma's first product is an in-ovo vaccination against Newcastle disease, a severe infection affecting domestic poultry.

What problem does Cinnaxole Pharma aim to solve in the poultry industry?

Cinnaxole Pharma aims to address the lack of efficient in-ovo vaccination against Newcastle disease, offering a solution that is more effective and less costly than traditional methods.